SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)

被引：0

作者：

Josep Gumà

Natalia Palazón-Carrión

Antonio Rueda-Domínguez

Silvia Sequero

Virginia Calvo

Ramón García-Arroyo

José Gómez-Codina

Marta Llanos

Natividad Martínez-Banaclocha

Mariano Provencio

机构：

[1] Hospital Universitari Sant Joan de Reus,Medical Oncology Department

[2] IISPV,Medical Oncology Department

[3] URV,Medical Oncology Department

[4] Hospital Universitario Virgen de la Macarena,Medical Oncology Department

[5] UGCI Medical Oncology,Medical Oncology Department

[6] Hospitales Universitarios Regional y Virgen de la Victoria,Medical Oncology Department

[7] IBIMA,Medical Oncology Department

[8] Hospital Universitario San Cecilio,Oncology Department

[9] Hospital Universitario Puerta de Hierro,undefined

[10] Complejo Hospitalario Universitario,undefined

[11] Hospital Universitari i Politècnic La Fe,undefined

[12] Hospital Universitario de Canarias,undefined

[13] Hospital General Universitario Dr. Balmis,undefined

[14] Institute for Health and Biomedical Research (ISABIAL),undefined

来源：

Clinical and Translational Oncology | 2023年 / 25卷

关键词：

Diffuse large B-cell lymphoma; Guideline; Diagnosis; Treatment;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Diffuse large B-cell lymphoma is the most frequent histological subtype of NHL and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hemopathologist is recommended to establish the diagnosis. Twenty years following its introduction, R-CHOP remains the standard first-line treatment. No modification of this scheme (increased chemotherapy dose intensity, new monoclonal antibodies, or the addition of immunomodulators or anti-target agents) has significatively improved the clinical outcomes, whereas therapy for recurrence or progression is evolving rapidly. The irruption of CART cells, polatuzumab vedotin, tafasitamab, and CD20/CD3 bispecific antibodies are changing the natural history of relapsed patients and will challenge R-CHOP as the benchmark for newly diagnosed patients.

引用

页码：2749 / 2758

页数：9

共 223 条

[1]

Dykewicz CA(2001)Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients Clin Infect Dis 33 139-144

[2]

Marcos-Gragera R(2010)Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain Ann Oncol 21 iii90-96

[3]

Pollán M(2012)Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain? Clin Transl Oncol 14 386-390

[4]

Chirlaque MD(2000)Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503-511

[5]

Gumà J(2004)Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 275-282

[6]

Sánchez MJ(2020)A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications Cancer Cell 37 551-568

[7]

Garau I(2014)Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification J Clin Oncol 32 3059-3068

[8]

Provencio M(2014)FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis Eur J Nucl Med Mol Imaging 41 565-574

[9]

Sabín P(1993)A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 987-994

[10]

Gómez Codina J(2010)Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era J Clin Oncol 28 2373-2380

← 1 2 3 4 5 6 7 8 9 10 →